Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/PDCD4_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/PDCD4_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/PDCD4_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/PDCD4_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/PDCD4_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/PDCD4_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/PDCD4_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/PDCD4_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/PDCD4_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/PDCD4_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:007030220 | Thyroid | HT | regulation of stress-activated protein kinase signaling cascade | 29/1272 | 195/18723 | 5.55e-05 | 1.07e-03 | 29 |
GO:000183710 | Thyroid | HT | epithelial to mesenchymal transition | 24/1272 | 157/18723 | 1.53e-04 | 2.34e-03 | 24 |
GO:00719015 | Thyroid | HT | negative regulation of protein serine/threonine kinase activity | 20/1272 | 120/18723 | 1.62e-04 | 2.43e-03 | 20 |
GO:007190019 | Thyroid | HT | regulation of protein serine/threonine kinase activity | 43/1272 | 359/18723 | 2.09e-04 | 3.01e-03 | 43 |
GO:000717818 | Thyroid | HT | transmembrane receptor protein serine/threonine kinase signaling pathway | 42/1272 | 355/18723 | 3.21e-04 | 4.20e-03 | 42 |
GO:004340925 | Thyroid | HT | negative regulation of MAPK cascade | 25/1272 | 180/18723 | 5.10e-04 | 6.14e-03 | 25 |
GO:000756916 | Thyroid | HT | cell aging | 20/1272 | 132/18723 | 5.90e-04 | 6.93e-03 | 20 |
GO:19012249 | Thyroid | HT | positive regulation of NIK/NF-kappaB signaling | 13/1272 | 69/18723 | 6.70e-04 | 7.61e-03 | 13 |
GO:000223725 | Thyroid | HT | response to molecule of bacterial origin | 41/1272 | 363/18723 | 9.54e-04 | 9.83e-03 | 41 |
GO:003249624 | Thyroid | HT | response to lipopolysaccharide | 39/1272 | 343/18723 | 1.11e-03 | 1.11e-02 | 39 |
GO:004876210 | Thyroid | HT | mesenchymal cell differentiation | 29/1272 | 236/18723 | 1.43e-03 | 1.35e-02 | 29 |
GO:19012226 | Thyroid | HT | regulation of NIK/NF-kappaB signaling | 17/1272 | 112/18723 | 1.44e-03 | 1.36e-02 | 17 |
GO:004632816 | Thyroid | HT | regulation of JNK cascade | 19/1272 | 133/18723 | 1.64e-03 | 1.50e-02 | 19 |
GO:00486608 | Thyroid | HT | regulation of smooth muscle cell proliferation | 23/1272 | 180/18723 | 2.57e-03 | 2.15e-02 | 23 |
GO:00550063 | Thyroid | HT | cardiac cell development | 14/1272 | 91/18723 | 3.23e-03 | 2.55e-02 | 14 |
GO:19040198 | Thyroid | HT | epithelial cell apoptotic process | 17/1272 | 121/18723 | 3.35e-03 | 2.60e-02 | 17 |
GO:00486598 | Thyroid | HT | smooth muscle cell proliferation | 23/1272 | 184/18723 | 3.40e-03 | 2.63e-02 | 23 |
GO:00380617 | Thyroid | HT | NIK/NF-kappaB signaling | 19/1272 | 143/18723 | 3.77e-03 | 2.81e-02 | 19 |
GO:00486623 | Thyroid | HT | negative regulation of smooth muscle cell proliferation | 12/1272 | 75/18723 | 4.46e-03 | 3.20e-02 | 12 |
GO:00350514 | Thyroid | HT | cardiocyte differentiation | 20/1272 | 156/18723 | 4.54e-03 | 3.23e-02 | 20 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PDCD4 | SNV | Missense_Mutation | | c.785N>T | p.Gly262Val | p.G262V | Q53EL6 | protein_coding | deleterious(0) | probably_damaging(0.976) | TCGA-A2-A25A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Cytoxan | SD |
PDCD4 | SNV | Missense_Mutation | | c.499N>C | p.Thr167Pro | p.T167P | Q53EL6 | protein_coding | tolerated(0.12) | benign(0.388) | TCGA-A8-A09M-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | paclitaxel | CR |
PDCD4 | SNV | Missense_Mutation | novel | c.923N>C | p.Gly308Ala | p.G308A | Q53EL6 | protein_coding | tolerated(0.07) | benign(0) | TCGA-AC-A3QP-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | femara | SD |
PDCD4 | SNV | Missense_Mutation | novel | c.1203N>T | p.Met401Ile | p.M401I | Q53EL6 | protein_coding | tolerated(0.07) | benign(0.076) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PDCD4 | SNV | Missense_Mutation | novel | c.8N>C | p.Val3Ala | p.V3A | Q53EL6 | protein_coding | tolerated_low_confidence(0.53) | benign(0) | TCGA-B6-A0IJ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PDCD4 | SNV | Missense_Mutation | rs376713943 | c.943N>G | p.Trp315Gly | p.W315G | Q53EL6 | protein_coding | deleterious(0) | probably_damaging(0.981) | TCGA-C5-A1BQ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | CR |
PDCD4 | SNV | Missense_Mutation | | c.356G>C | p.Gly119Ala | p.G119A | Q53EL6 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-DG-A2KM-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
PDCD4 | SNV | Missense_Mutation | novel | c.703N>A | p.Asp235Asn | p.D235N | Q53EL6 | protein_coding | deleterious(0.05) | benign(0.229) | TCGA-HM-A4S6-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | CR |
PDCD4 | SNV | Missense_Mutation | | c.888N>A | p.Asp296Glu | p.D296E | Q53EL6 | protein_coding | tolerated(0.25) | benign(0) | TCGA-LP-A4AW-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
PDCD4 | SNV | Missense_Mutation | rs375978756 | c.250N>A | p.Ala84Thr | p.A84T | Q53EL6 | protein_coding | tolerated(0.38) | benign(0) | TCGA-MA-AA42-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |